相关实验视频
Updated: Sep 9, 2025

09:09
In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
1.8K
发现关键生物标志物,潜在的治疗目标和心力衰竭的深度学习模型
Ming Du1, Shuang He1, Jiaojiao Liu1
1Department of Cardiovascular Medicine, Liaoning Provincial People's Hospital, Shenyang, China.
PloS one
|September 3, 2025
概括
研究人员确定了四种关键基因 (ITIH5,ISLR,ASPN,FNDC1) 和两种潜在的心力衰竭药物. 一个深度学习模型被开发用于HF诊断,为疾病机制和治疗目标提供了洞察力.
科学领域:
- 基因组学和生物信息学
- 心血管研究
- 计算生物学
背景情况:
- 心力衰竭 (HF) 是一个主要的公共卫生问题,死亡率和发病率很高.
- 基因测序揭示了许多与HF发展相关的基因.
- 了解HF的分子基础对于开发有效治疗至关重要.
研究的目的:
- 确定关键基因和潜在的心力衰竭治疗点.
- 开发一种新的基于深度学习的HF诊断模型.
- 阐明HF进展背后的分子机制.
主要方法:
- 使用基因表达总 (GEO) 数据进行差异基因表达分析.
- 权重基因表达网络分析 (WGCNA) 和功能丰富.
- 机器学习,蛋白质相互作用 (PPI) 分析和GSEA.
- 深度学习 (CNN) 用于诊断模型开发和单细胞RNA测序.
主要成果:
- 四个关键基因 (ITIH5,ISLR,ASPN,FNDC1) 已被确定为与HF有显著关联.
- 一个基于CNN的诊断模型在识别HF方面表现出很高的准确性.
- 这些基因在HF患者的心肌细胞中显示出一致的上调.
- 发现了针对已识别的基因的两个潜在的治疗小分子.
结论:
- 该研究确定了新的HF生物标志物和潜在的治疗药物.
- 这些发现提供了有关HF病变和潜在治疗策略的见解.
- 开发的诊断模型显示出在HF检测中临床应用的前景.
相关概念视频
Heart Failure IV: Classification and Diagnostic Evaluation
32
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
32
Heart Failure II: Pathophysiology
37
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
37
Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
Pathophysiology of Heart Failure
1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505

